19 Apr 2016 15:16
VERONA PHARMA PLC - Change of Registered OfficeVERONA PHARMA PLC - Change of Registered Office
PR Newswire
London, April 19
Verona Pharma plc
("Verona Pharma" or the "Company")
Change in Registered Office
19 April 2016, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces that its registered office address has changed to: One Central Square, Cardiff, CF10 1FS.
For further information, please contact:
Verona Pharma plc Jan-Anders Karlsson, CEO | Tel: +44 (0)20 7863 3300 |
N+1 Singer Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 |
FTI Consulting Simon Conway / Julia Phillips | Tel: +44 (0)20 3727 1000 |
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis.Â
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma.Â
Verona Pharma is also building a broader portfolio of RPL554-containing products to maximise its benefit to patients and its value. This includes the very significant markets for COPD and asthma maintenance therapy. In addition, the Company is exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing and has received a Venture and Innovation Award from the UK Cystic Fibrosis Trust.